Ajanta Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/05/2026 ,inter alia, to consider and approve Financial Results for the quarter and year ended 31st March 2026.

pdf

Ajanta Pharma Ltd.

06 Apr 2026

2905.50

2.93%

Company Update

Ajanta Pharma Ltd - 532331 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

BSE India

Pls find enclosed herewith Certificate under Reg. 74(5) of SEBI (DP) Regulations.

pdf

Ajanta Pharma Ltd.

04 Apr 2026

2905.50

2.93%

SAST

Ajanta Pharma Ltd - 532331 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, …

BSE India

The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on April 03, 2026 for Aayush Agrawal, trustee Aayush Agrawal Trust

pdf

Ajanta Pharma Ltd.

01 Apr 2026

2905.50

2.93%

Corp. Note

Ajanta Pharma Ltd - 532331 - Format of the Initial Disclosure to be made by an …

BSE India

Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompanyAjanta Pharma Ltd 2CIN NO.L24230MH1979PLC022059 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 0.00 4Highest Credit Rating during the previous FY A1+ 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)CARE RATINGS LIMITED 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkNSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: Gaurang Shah Designation: Sr VP Legal and Company Secretary EmailId: gaurang.shah@ajantapharma.com Name of the Chief Financial Officer: Arvind Agrawal Designation: Chief Financial Officer EmailId: gaurang.shah@ajantapharma.com Date: 01/04/2026 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.

pdf

Ajanta Pharma Ltd.

01 Apr 2026

2905.50

2.93%

SAST

Ajanta Pharma Ltd - 532331 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, …

BSE India

The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on March 31, 2026 for Ravi Agrawal, trustee Ravi Agrawal Trust

pdf

Ajanta Pharma Ltd.

27 Mar 2026

2905.50

2.93%

SAST

Ajanta Pharma Ltd - 532331 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, …

BSE India

The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on March 27, 2026 for Aayush Agrawal & Others

pdf

Ajanta Pharma Ltd.

26 Mar 2026

2905.50

2.93%

SAST

Ajanta Pharma Ltd - 532331 - Closure of Trading Window

BSE India

Please find enclosed herewith intimation w.r.t Closure of Trading Window

pdf

Ajanta Pharma Ltd.

23 Mar 2026

2905.50

2.93%

SAST

Ajanta Pharma Ltd - 532331 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, …

BSE India

The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on March 23, 2026 for Ravi Agrawal, trustee Ravi Agrawal Trust

pdf

Is Ajanta Pharma Ltd. worth buying?

195 Votes:

Buy 76.92%

Sell 16.41%

Hold 6.67%

RESEARCH REPORTS

Buy SEE REPORTS >

pdf

Buy SEE REPORTS >

pdf